Novavax (NVAX) said Wednesday it believes its biologics license application for its COVID-19 vaccine is "approvable" by the US Food and Drug Administration based on ongoing discussions.
The company said the FDA recently asked for a post-marketing commitment to collect additional clinical data.
Novavax said it will work quickly to comply with the request and obtain final approval.
Shares of Novavax rose 12% in recent premarket activity Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。